Literature DB >> 6135489

Mechanism of antihypertensive action of ketanserin in man.

I W Reimann, J C Frölich.   

Abstract

A randomised double blind crossover study was carried out to determine whether ketanserin, a serotonin antagonist with an antihypertensive action in animals, has an alpha 1 adrenergic mediated antihypertensive effect in man. Steady state plasma ketanserin concentrations (mean 88 (SD 19) micrograms/1) and cardiovascular responses measured in five healthy volunteers showed that therapeutic doses of ketanserin significantly antagonised the alpha 1 receptor mediated increase in arterial blood pressure after treatment with methoxamine. Thus the antihypertensive action of ketanserin in man appears to originate from a blockade of peripheral vascular alpha 1 receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135489      PMCID: PMC1548913          DOI: 10.1136/bmj.287.6389.381-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  23 in total

Review 1.  Clinical pharmacokinetics of ketanserin.

Authors:  B Persson; J Heykants; T Hedner
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Antihypertensive treatment with ketanserin shows no evidence of vascular serotonin2-receptor and alpha 1-adrenoceptor blockade.

Authors:  G J Blauw; C J Doorenbos; T A Bruning; P van Brummelen; P A van Zwieten
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Pharmacological manipulation of cardiovascular responses to lower body negative pressure.

Authors:  G Perko; J F Schmidt; J Warberg; N H Secher
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

5.  The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.

Authors:  H Ahlman; A Dahlström; K Grönstad; L E Tisell; K Oberg; M J Zinner; B M Jaffe
Journal:  Ann Surg       Date:  1985-01       Impact factor: 12.969

6.  Response to tilting in hypertensive patients receiving ketanserin.

Authors:  L A Ferrara; F Pasanisi; M L Fasano; S Soro
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.

Authors:  F M Williams; J E Leeser; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

8.  Profound hypotension after the first dose of ketanserin.

Authors:  P C Waller; H A Cameron; L E Ramsay
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401

9.  The mechanism of the antihypertensive effects of ketanserin: a comparison with metoprolol.

Authors:  E Casiglia; R Gava; A Semplicini; P Nicolin; A C Pessina
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

10.  Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.

Authors:  J R Zabludowski; C Zoccali; C G Isles; G D Murray; J I Robertson; G C Inglis; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.